Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening plasma HIV-1 RNA ≥500 copies/mL~* ART-experienced, INI-experienced, DTG naïve~* Experienced virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen~* The subject's HIV-1 shows resistance to RAL or ELV at Screening or at prior time point of virological failure on RAL or ELV~* Documented resistance to at least one drug from each of three or more of all approved classes of ART~* Be able to receive at least one fully active drug as part of the OBR from Day 8~* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)~* Willing and able to understand and provide signed and dated written informed consent prior to Screening.~Exclusion Criteria:~* Women who are pregnant or breast feeding~* An active AIDS-defining condition at Screening (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ \<200c/mm3)~* Moderate to severe hepatic impairment as defined by Child-Pugh classification~* Anticipated need for HCV therapy during the first 24 weeks of the study~* Recent history of any upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding~* Allergy or intolerance to the study drugs or their components or drugs of their class~* Malignancy within the past 6 months~* Treatment with an HIV-1 therapeutic vaccine within 90 days of Screening~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening~* Treatment with any agent, other than licensed ART, with documented activity against HIV-1 in vitro within 28 days of first dose of investigational product~* Treatment with etravirine, efavirenz, or nevirapine within 14 days of Day 1(etravirine may be used if coadministered with lopinivir/ritonavir or darunavir/ritonavir)~* Treatment with tipranivir/ritonavir, fosamprenavir, or fosamprenavir/ritonavir within 28 days prior to Screening~* Verified Grade 4 laboratory abnormality at Screening~* ALT\> 5 times the upper limit of normal (ULN) at Screening~* ALT ≥ 3X ULN and bilirubin \> 1.5 X ULN (with 35% direct bilirubin) at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dolutegravir (Type: EXPERIMENTAL): dolutegravir plus background antiretroviral therapy optimised at Day 8

Based on this trial design, predict the completion outcome and termination type (if applicable).